P Pharming Group NV
P
Avatud
1.168 2.01
Ülevaade
Aktsiahinna muutus
24h
Min
1.1360000000000001
Max
1.171
Sissetulek | 21M 23M |
|---|---|
Müük | 28M 118M |
P/E Sektori keskmine | 37.417 51.78 |
Aktsiakasum | 0.03 |
Kasumimarginaal | 19.048 |
Töötajad | 407 |
EBITDA | 26M 31M |
Turukapital | 48M 794M |
|---|---|
Eelmine avamishind | -0.84 |
Eelmine sulgemishind | 1.168 |
Pharming Group NV Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pharming Group NV Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.